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Introduction: Epidermal growth factor receptor (EGFR) tyrosine 
kinase inhibitors and Met inhibitors have enabled progress in the 
management of advanced non–small-cell lung cancer (NSCLC). 
However, the clinical benefits of these agents are not uniform across 
the NSCLC spectrum. Thus, we evaluated the prognostic effect 
of mesenchymal-epithelial transition (MET) expression in Asian 
NSCLC patients with or without EGFR mutation.
Methods: Frozen tumor tissues were collected from 92 patients 
with surgical resection and 10 with lymph node biopsy. Mutations in 
exons 18–21 in the EGFR–tyrosine kinase domain and MET expres-
sion were analyzed by using sequencing and immunohistochemistry, 
respectively.
Results: The MET overexpression rate was 51% in NSCLC patients. 
MET-positive patients had poorer overall survival than MET-negative 
patients (29.8 versus 69.1 months, χ2 = 7.420, p = 0.006) in patients 
with wild-type EGFR. However, no statistically significant differ-
ence was found in EGFR mutant patients (35.0 versus 35.9 months, 
χ2 = 0.114, p = 0.735). Multivariate analysis showed that stage, MET 
expression, and sex were independent prognostic factors in patients 
with wild-type EGFR (χ2 = 32.896, p < 0.001).
Conclusions: These results suggest that MET expression has differ-
ent prognostic significance in patients with differing EGFR muta-
tion status. Whether MET inhibitors should be given early to NSCLC 
patients with EGFR wild-type needs further investigation.
Key Words: Non–small-cell lung cancer, Epidermal growth factor 
receptor, MET expression.
(J Thorac Oncol. 2014;9: 725–728)
Mutations in the epidermal growth factor receptor (EGFR) best illustrate the therapeutic relevance of molecular 
clusters. In Europe, the frequency of activating EGFR muta-
tions in non–small-cell lung cancer (NSCLC) varies between 
9% and 15%, whereas in East Asian countries, the rate of EGFR 
mutation patients is higher, up to 30%.1 EGFR status strongly 
predicts the efficacy of EGFR inhibitors, with response rates 
higher than 70% seen in some studies.2 Previous studies have 
also identified that mesenchymal-epithelial transition (MET) 
oncogene amplification is a relevant mechanism responsible for 
resistance, apart from the secondary EGFR T790M mutation.3
The MET pathway is dysregulated via overexpression, 
gene amplification, ligand-dependent activation, and muta-
tion in many human malignancies, and regulates tumorige-
nicity, cellular proliferation, motility, invasion, antiapoptotic 
responses, and dissemination.4 In large cohorts of patients with 
NSCLC not previously treated with EGFR–tyrosine kinase 
inhibitors, MET amplification rate is 13.7% to 100%. This 
variability might be related to differences in methods and cut-
off values used to assess and define amplification.5,6Although 
both EGFR and MET have gained considerable attention in the 
targeted therapy of NSCLC, there have been few  large-scale 
studies of the prognostic significance of MET expression and 
EGFR mutations status in the same cohort of NSCLC patients. 
Thus, we investigated the prognostic role of MET expression 
and EGFR mutation status in a group of NSCLC patients.
PATIENTS AND METHODS
Patients and Tissues
Seven hundred eighty-two patients between May 2003 
and October 2011 were retrospectively selected as candidates 
for c-MET immunohistochemistry at Guangdong General 
Hospital, China. Among them 120 cases that had enough 
tumor specimens were included. Ten cases revealed tis-
sue necrosis, and eight cases of tumor cells were less than 
50% for pathological evaluation. Finally, 102 patients were 
enrolled in the study. Written informed consent was obtained 
from each patient. Resection samples were snap-frozen in liq-
uid nitrogen and stored at −80°C until analyzed. All patients 
were chemonaive and tyrosine kinase inhibitors–naive at the 
time of surgery.
EGFR Mutation Analysis
Mutations in exons 18–21 of the tyrosine kinase domain 
of the EGFR gene were detected using sequencing method. 
Polymerase chain reaction products were purified and the 
BigDye Terminator v3.1 Cycle Sequencing kit (Applied 
Biosystems, Foster City, CA) was used for sequencing with 
an ABI PRISM 3730 Genetic Analyzer (Applied Biosystems). 
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Both forward and reverse sequencing reactions were per-
formed using the respective primers.
Immunohistochemical Staining 
for MET Protein Expression
Sections (4–6 μm) of each specimen were taken from 
frozen specimens mounted in optimum cutting temperature 
(OCT) compound (Tissue-Tek, Sakura Finetek USA, Inc., 
Torrance, CA), monoclonal MET primary antibody (# 8198; 
Cell Signaling Technology, Danvers, MA) with a 1:500 dilution 
was used. Negative controls were prepared by substituting the 
primary antibody with 1×phosphate-buffered saline.
Semiquantitative analysis of MET immunoreactivity 
was performed using the H-score system. For the H-score 
method, the entirety of each slide was assessed by light 
microscopy. The intensity score was defined as: 0 = negative, 
1 = weak, 2 = moderate, or 3 = strong positive. The fraction 
of positive cells at each intensity was estimated as a percent-
age. The H-score was the cross-product of the intensity score 
and the fraction score, with the score ranging from 0 to 300. 
Immunohistochemical findings were analyzed by two indepen-
dent investigators, blinded to the clinical data. If discrepancies 
occurred, a consensus score was reached thorough discussion.
Statistical Analyses
Overall survival was determined from the date of surgery 
to the date of death by any cause. Univariate analysis was con-
ducted using the Kaplan–Meier method, and differences among 
subgroups were compared using the log-rank test. The Cox pro-
portional hazards model was used to identify independent prog-
nostic factors. All statistical tests were two-sided, and p values 
less than 0.05 were taken to indicate statistical significance.
RESULTS
Patients’ Characteristics
In total, 102 NSCLC patients with a median age of 62 
years (range, 32–79) were enrolled. Most patients were men 
(72.0%) and in early pathological stages (52.9%, stages I–II; 
Table 1).
Association between MET Protein 
Expression and EGFR Mutation Status
Of the 102 patients, 30 (29.4%) harbored EGFR muta-
tions. MET immunoreactivity was detected predominantly 
in the membranes and cytoplasm of tumor cells, and it was 
localized in the basolateral aspect of the cytoplasm (Fig. 1). 
According to the H-score method, the median score for MET 
expression was 60 (range, 0–300). Thus, 60 was used as the cut-
off for classification of positive and negative MET expression. 
In total, 52 cases (51.0%) were MET positive, and 50 cases 
(49.0%) were negative; 56.7% of the EGFR mutant patients 
and 48.6% of EGFR wild-type patients expressed high levels 
of membranous MET, respectively (χ2 = 0.550, p = 0.458).
Survival Analyses
In all patients, the MET-positive patients had poorer 
survival than negative patients (33.0 versus 47.2 months, 
χ2 = 5.247, p = 0.022). In the subgroup of patients with 
 wild-type EGFR, MET-positive patients had poorer sur-
vival than  MET-negative patients (29.8 versus 69.1 months, 
χ2 = 7.420, p = 0.006). However, in the subgroup of patients 
with EGFR mutations, no statistically significant difference 
was found between them (35.0 versus 35.9 months, χ2 = 0.114, 
p = 0.735; Fig. 2).
To further assess whether MET was a prognostic bio-
marker of the subgroup of patients with wild-type EGFR, mul-
tivariate analysis was performed using the Cox proportional 
hazards model, including age, sex, smoking status, stage, 
histology, and MET expression (entry: p = 0.05, removal: 
p = 0.10, forward: Wald). Stage, MET expression, and sex 
were the three independent prognostic factors in patients with 
 wild-type EGFR (χ2 = 32.896, p < 0.001; Table 2).
DISCUSSION
Now there are two methods—H-score and MetMab trial 
for evaluating MET overexpression. H-core is a semiquantita-
tive scoring and provides an overall score (0–300) based on 
the sum of ordinal weighted percentiles of cells stained. Some 
laboratories including our own, prefer the H-score because of 
its wide dynamic range and use of weighted percentiles. We 
used H-Score in our study.
Our study showed that MET was highly expressed in 
51% of the cases, similar to another report.7 EGFR muta-
tions can activate MET protein in untreated NSCLC.8 EGFR 
signaling may regulate MET protein in cell lines through the 
hypoxia-inducible factor–1α pathway.9 The results from our 
study shown there was a trend toward higher levels of mem-
branous MET in patients with EGFR mutations. These studies 
TABLE 1.  Clinical Characteristics of the Patients
Characteristic n (%) EGFR M (%) EGFR WT (%) p
Overall 102 30 (29.4) 72 (70.6)
Age (yrs)
  Median 62 (32–79)
  <65 59 (57.8) 15 (25.4) 44 (74.6)
 ≥65 43 (42.2) 15 (34.9) 28 (65.1) 0.300
Sex
  Male 73 (72.0) 16 (21.9) 57 (78.1)
  Female 29 (28.0) 14 (48.3) 15 (51.7) 0.008
Smoking status
  Smoker 47 (46.0) 8 (17.0) 39 (83.0)
  Nonsmoker 55 (54.0) 22 (40.0) 33 (60.0) 0.011
Histology
  ADC 69 (67.6) 26 (37.7) 43 (62.3)
  SCC 27 (26.4) 3 (11.1) 24 (88.9)
  LCC 6 (6.0) 1 (16.7) 5 (83.3) 0.029
Staging
  I + II (operable) 54 (52.9) 15 (27.8) 39 (72.2)
  III (operable) 38 (37.3) 11 (28.9) 27 (71.1)
  IV(biopsy) 10 (9.8) 4 (40.0) 6 (60.0) 0.732
EGFR, epidermal growth factor receptor; M, mutation; WT, wild type; ADC, 
adenocarcinoma; SCC, squamous cell carcinoma; LCC, large-cell carcinoma.
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suggest that the MET pathways might differ with different 
EGFR mutation status.
MET overexpression has been shown to be a negative 
prognostic factor in NSCLC.6,10 Furthermore, the multivariate 
analysis in our study revealed that positive MET expression 
was an independent poor prognostic factor in NSCLC patients 
with wild-type EGFR but not in patients with EGFR muta-
tion. Thus, the prognostic implications of MET expression 
may differ depending on the EGFR genetic profile. However, 
the mechanisms remain unclear. Cross-talk between the MET 
and EGFR pathways might be involved.
MET has been considered as a promising therapeutic 
target for anticancer therapy. With the development of sev-
eral kinds of MET inhibitors, promising results have begun to 
emerge.11–14 OAM4558g, a Met antibody, was demonstrated to 
be effective in patients with positive MET expression, whereas 
it was harmful to patients who were MET IHC-negative.7 
However, in our study, MET expression had no prognostic sig-
nificance in EGFR-mutated patients.
In summary, to our knowledge, this is the first report 
of the prognostic significance of MET expression in patients 
based on EGFR mutation status. Our data suggest that posi-
tive MET expression was an independent poor prognostic fac-
tor in patients negative for EGFR mutations. This has at least 
potential implications for clinical practice. Further studies are 
needed to certify whether MET inhibitors should be given 
as first-line treatment to patients with MET expression and 
 wild-type EGFR.
FIGURE 1.  Immunoreactivity of 
MET in tyrosine kinase inhibitor–naive 
non–small-cell lung cancer samples. 
MET was identified in the membranes 
and cytoplasm of cancerous cells. A, 
H-score = 270; B, H-score = 180; C, 
H-score = 60; D, H-score = 0 (200×). 
FIGURE 2.  Survival time of MET overexpression in non–small-cell lung cancer patients with differing EGFR mutation status, in 
(A) all patients, (B) patients with wild-type EGFR, and (C) patients with EGFR mutations. EGFR, epidermal growth factor reactor; 
MET, mesenchymal-epithelial transition; MST, median survival time.
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